Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aubagio in relapsing MS patients switching from natalizumab
NCT01970410Phase 4Completed
- Start
- Oct 2013
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teriflunomide in multiple sclerosis (MS). Primary endpoint: Number of Participants Relapse Free at 24 Months. Started Oct 2013; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01970410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970410.